NCT02002208View on ClinicalTrials.gov

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

February 29, 2016

Conditions
Atopic Dermatitis
Interventions
DRUG

OC000459

Oral CRTH2 antagonist

Trial Locations (1)

Unknown

University of Sheffield, Sheffield

Sponsors
All Listed Sponsors
lead

Atopix Therapeutics, Ltd.

INDUSTRY

NCT02002208 - Effect of OC000459 on Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter